Prometheus Biosciences

Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA .

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Precision IBD is a Biotechnology company and operator of a drug development precision medicine company intended to develop therapeutics for inflammatory bowel diseases.

Prometheus Biosciences (NASDAQ: RXDX ) stock is rocketing higher on Wednesday after reporting results from its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies of PRA023. PRA023 is a treatment in development for ulcerative colitis (UC) and Crohn's disease ( CD ).

Why Is Prometheus Biosciences (RXDX) Stock Up 175% Today?

Prometheus Bio reported promising results from two inflammatory disease studies on Wednesday, and RXDX stock catapulted higher. The post Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease appeared first on Investor's Business Daily.

Prometheus Biosciences Catapults 176% On Promising Results In Irritable Bowel Disease

Shares of Prometheus Biosciences Inc. RXDX, -4.40% soared 177.0% in premarket trading on Wednesday after the company said it will advance an experimental therapy into Phase 3 clinical trials for ulcerative colitis and Crohn's disease next year. The treatment, PRA023, was both safe and efficacious in a pair of Phase 2 clinical trials for the same conditions, Prometheus said in a news release.

Prometheus shares rally 177% as it prepares to move drug into Phase 3 studies

MongoDB

Even as broader markets fell, these companies announced great news.

These 2 Nasdaq Stocks Knocked It Out of the Park Wednesday

– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p

Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

The company's lead pipeline candidate is facing competition from a Pfizer-backed drug.

Why Shares of Prometheus Biosciences Slumped This Week

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates

- On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2022 -

Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

AppLovin Corp

Enovix Corporation

NeoGenomics

1Life Healthcare

Signify Health

Sotera Health

Scotts Miracle-Gro

Verve Therapeutics

WeWork

Mid-cap companies are those that fall between small and large cap companies. Thus, they are more stable than small-cap companies and, at the same time, offer higher growth opportunities than large-cap companies.

These Were The Five Best And Worst Performing Mid-Cap Stocks In Q3 2022

- PRA052 is a monoclonal antibody blocking CD30 ligand that has a pleiotropic effect on both innate and adaptive immunity and targets a pathway that is distinct from TNF -

Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052

Pfizer

A little-known biotech chasing Pfizer's tail could soon skyrocket.

Can This Tiny Biotech Take On Pfizer?

AbbVie

ADMA Biologics

Geron

SIGA Technologies

Voyager Therapeutics

Axsome Therapeutics

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

7 Top-Rated Biotech Stocks to Buy for Q4

SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will conduct fireside chats at the following healthcare conferences:

Prometheus Biosciences to Participate at September Healthcare Conferences

Prometheus Biosciences, Inc. (RXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Prometheus Biosciences, Inc. (RXDX) a New Buy Stock

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 6.52% and 81.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Prometheus Biosciences, Inc. (RXDX) Reports Q2 Loss, Tops Revenue Estimates

- Both topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results expected concurrently in 4Q 2022  -

Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

- The event will feature Prometheus management and key opinion leader presentations on PR600 target unveiling, scientific rationale, and corresponding therapeutic candidate, PRA052 -

Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022

- G lobal Phase 2 placebo-controlled trial enrolled twice as fast as the industry average, establishing a roadmap for future studies -

Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis

- Enrollment completed ahead of schedule for APOLLO-CD Phase 2a study of PRA023 in Crohn's disease patients -

Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies

- Advanced and expanded development of PRA023 across three immune-mediated indications -

Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

- First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways -

Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn's disease expected in fourth quarter 2022 -

Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will conduct a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET.

Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

Allogene Therapeutics Inc

Moderna

Theseus Pharmaceuticals

UnitedHealth Group

Check out these health care firms taking center stage in the stock market now.

Top Stocks To Invest In Right Now? 5 Health Care Stocks To Watch

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that Mark McKenna, Chairman and CEO, will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Wednesday, January 12, at 1:30 p.m. EST.

News for Prometheus Biosciences Stock (RXDX)